Valuation: TAUNS Laboratories,Inc.

Market Cap 51.91B 329M 294M 269M 245M 460M 31.14B 469M 3.22B 1.3B 16.44B 1.23B 1.21B P/E 2026 *
9.77x
P/E 2027 * 16.1x
Enterprise Value 59.91B 380M 339M 311M 283M 530M 35.93B 541M 3.71B 1.5B 18.97B 1.42B 1.39B EV / Sales 2026
-
EV / Sales 2027 * 3.89x
Free-Float
30.14%
Yield 2026 *
7.26%
Yield 2027 * 5.86%
1 day-1.02%
1 week-3.19%
Current month-1.02%
1 month-4.52%
3 months+2.75%
6 months-0.61%
Current year-4.52%
1 week 485
Extreme 485
499
1 month 485
Extreme 485
525
Current year 463
Extreme 463
568
1 year 463
Extreme 463
577
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-30
General Counsel 58 -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 51 2014-04-30
Director/Board Member 53 2016-03-31
Director/Board Member 43 2020-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-3.19%-12.43% - 329M
+3.73%+5.03%-10.89%+14.80% 191B
+2.85%+4.75%+9.47%+37.73% 122B
+5.12%+0.22%-13.88%+10.27% 117B
-0.54%+2.23%-41.37%+6.66% 96.21B
+2.12%+2.38%+0.01%+75.79% 64.47B
-5.48%-5.11%-1.24%+61.88% 52.51B
+0.36%+1.13%+11.13%-22.40% 54.1B
+21.85%+17.79%+6.69%+60.13% 52.91B
-0.81%+4.10%+1.66%-10.56% 35.65B
Average +2.81%+3.16%-5.08%+26.03% 78.51B
Weighted average by Cap. +3.31%+3.94%-7.11%+24.18%

Financials

2026 2027 *
Net sales 14.76B 93.49M 83.47M 76.6M 69.68M 131M 8.85B 133M 915M 369M 4.67B 351M 343M 16.1B 102M 91.06M 83.56M 76.01M 143M 9.66B 145M 998M 402M 5.1B 383M 375M
Net income 5.2B 32.96M 29.42M 27M 24.56M 46.05M 3.12B 46.97M 322M 130M 1.65B 124M 121M 3.21B 20.35M 18.17M 16.67M 15.16M 28.43M 1.93B 29M 199M 80.26M 1.02B 76.37M 74.74M
Net Debt 7.99B 50.65M 45.22M 41.5M 37.75M 70.77M 4.8B 72.18M 496M 200M 2.53B 190M 186M 10.67B 67.6M 60.36M 55.39M 50.38M 94.46M 6.4B 96.34M 662M 267M 3.38B 254M 248M
Projected Income Statement - Annual - TAUNS Laboratories,Inc.
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26-11-02 JP¥486.00 -1.02% 137,900
26-10-30 JP¥491.00 -0.20% 105,300
26-10-29 JP¥492.00 0.00% 205,300
26-10-28 JP¥492.00 -1.20% 204,600
26-10-27 JP¥498.00 -0.80% 145,500
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - TAUNS Laboratories,Inc.
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
486.00JPY
Average target price
420.00JPY
Spread / Average Target
-13.58%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - TAUNS Laboratories,Inc.
  1. Stock Market
  2. Stocks
  3. 197A Stock